Literature DB >> 12449723

A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer.

Yongrong Mao1, Jianping Wu, Naining Wang, Lanxiang He, Chuanjing Wu, Qimin He, Sven Skog.   

Abstract

To explore the expression of cytosolic thymidine kinase 1 (TK1) as a cell proliferative marker in human breast cancers, immunohistochemistry was used to detect the expression of TK1 in 52 malignant breast lesions, 20 benign breast lesions, and 16 normal breast tissues. The results were compared to the expression of proliferating cell nuclear antigen (PCNA) in the same specimens. The TK1-labelling index (TK1-LI) and PCNA-labeling index (PCNA-LI) were significantly higher in malignant lesions than in nonmalignant lesions (p < 0.0001 and p < 0.0013, respectively). The TK1-LI (78.9%) in malignant lesions was higher compared to PCNA-LI (64.5%). No significant difference was found for TK1-LI and PCNA-LI between benign lesions and normal tissues. Concerning the tumor stages and the tumor grades, TK1-LI showed a significant correlation with the increased tumor stages (p = 0.023) and tumor grades (p = 0.009). However, PCNA-LI was neither significantly different in tumor stages (p = 0.062) nor in tumor grades (p = 0.073). We conclude that TK1 might be a more accurate marker than PCNA for estimation of cell proliferation and malignant potentials in breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12449723     DOI: 10.1081/cnv-120005905

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  7 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.

Authors:  James Meehan; Mark Gray; Carlos Martínez-Pérez; Charlene Kay; Jimi C Wills; Ian H Kunkler; J Michael Dixon; Arran K Turnbull
Journal:  J Pers Med       Date:  2021-08-14

3.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

Review 4.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

5.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

6.  Thymidine kinase 1 upregulation is an early event in breast tumor formation.

Authors:  Melissa M Alegre; Richard A Robison; Kim L O'Neill
Journal:  J Oncol       Date:  2012-06-19       Impact factor: 4.375

7.  Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Authors:  Nusayba Bagegni; Shana Thomas; Ning Liu; Jingqin Luo; Jeremy Hoog; Donald W Northfelt; Matthew P Goetz; Andres Forero; Mattias Bergqvist; Jakob Karen; Magnus Neumüller; Edward M Suh; Zhanfang Guo; Kiran Vij; Souzan Sanati; Matthew Ellis; Cynthia X Ma
Journal:  Breast Cancer Res       Date:  2017-11-21       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.